Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles
  • Search Articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Sensory neuron BRAF mediates opioid-induced hyperalgesia and tolerance via presynaptic NMDA receptor hyperactivity
Daozhong Jin, Hong Chen, Yuying Huang, Shao-Rui Chen, Hui-Lin Pan
Daozhong Jin, Hong Chen, Yuying Huang, Shao-Rui Chen, Hui-Lin Pan
View: Text | PDF
Research Article Neuroscience Oncology

Sensory neuron BRAF mediates opioid-induced hyperalgesia and tolerance via presynaptic NMDA receptor hyperactivity

  • Text
  • PDF
Abstract

Opioids are essential analgesics for managing severe pain but can paradoxically increase pain sensitivity (hyperalgesia) and diminish analgesic efficacy (tolerance). Hyperactivity of NMDA-type glutamate receptors (NMDARs) at primary afferent terminals in the spinal cord contributes to both phenomena; however, the underlying signaling mechanisms remain unclear. Here, we report that morphine administration in rats promoted the translocation of monomeric BRAF, an oncogenic kinase, from the dorsal root ganglion (DRG) to spinal cord synaptosomes, leading to increased MEK-ERK phosphorylation at nociceptor central terminals. BRAF physically interacted with NMDARs in both rat and human spinal cords. Inhibition of BRAF activity with vemurafenib reversed morphine-induced NMDAR phosphorylation and synaptic localization of α2δ-1–bound NMDARs. Vemurafenib also abolished morphine-induced presynaptic NMDAR hyperactivity in spinal dorsal horn neurons. Correspondingly, conditional Braf knockout in DRG neurons normalized morphine-enhanced NMDAR phosphorylation, synaptic trafficking of α2δ-1–bound NMDARs, and NMDAR hyperactivity in the spinal cord. Furthermore, pharmacological inhibition of BRAF or MEK, or Braf deletion in DRG neurons, enhanced morphine analgesia while mitigating morphine-induced hyperalgesia and tolerance. These findings identify BRAF overactivity at nociceptor central terminals as a key mediator of opioid-induced NMDAR hyperactivity. Clinically approved BRAF inhibitors could be repurposed to enhance opioid analgesia while minimizing adverse effects.

Authors

Daozhong Jin, Hong Chen, Yuying Huang, Shao-Rui Chen, Hui-Lin Pan

×

Figure 7

Inhibition of BRAF or MEK activity or BRAF knockdown reduces morphine-induced hyperalgesia and tolerance.

Options: View larger image (or click on image) Download as PowerPoint
Inhibition of BRAF or MEK activity or BRAF knockdown reduces morphine-in...
(A and B) Time course of the effect of vemurafenib (VEM, A) or selumetinib (SEL, B) on morphine-induced hyperalgesia and tolerance. Rats were intraperitoneally injected with morphine (Mor, 5 mg/kg) twice daily for 7 days. VEM (10 mg/kg) or SEL (10 mg/kg) was intraperitoneally injected 15 minutes prior to each morphine injection daily. Nociceptive threshold and latency were tested before (baseline) and 30 minutes after the first morphine injection daily. (C and D) Time course of the acute analgesic effect of morphine in rats cotreated with VEM (C) or SEL (D). Nociceptive threshold and latency were tested after the first morphine injection on day 1 and day 7. (E) Flowchart diagram shows the timeline of injection of siRNA (3 μg, intrathecally, once daily) and morphine (5 mg/kg, i.p., twice daily) used for behavioral testing. Braf-specific siRNA or control siRNA were injected 15 minutes prior to the first morphine injection daily. (F) Time course of morphine-induced hyperalgesia and tolerance in rats treated with Braf-specific siRNA or control (Cont) siRNA (n = 9 rats per group). Pressure withdrawal threshold and thermal withdrawal latency were measured before (baseline) and 30 minutes after the first morphine (Mor) injection daily on days 1–7. (G) Time course of the acute analgesic effect produced by the first morphine injection on day 1 and day 7 in rats treated with Braf-specific siRNA or control (Cont) siRNA (n = 9 rats per group). *P < 0.05, **P < 0.01, ***P < 0.001 versus respective values at day 1 or time (min) 0; #P < 0.05, ##P < 0.01, ###P < 0.001 versus respective control groups at the same time point (2-way ANOVA followed by Tukey’s post hoc test).

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts